#testosterone — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #testosterone, aggregated by home.social.
-
DATE: May 11, 2026 at 12:00PM
SOURCE: PSYPOST.ORG** Research quality varies widely from fantastic to small exploratory studies. Please check research methods when conclusions are very important to you. **
-------------------------------------------------TITLE: The testosterone myth? Large analysis finds no link between the “macho” hormone and risk-taking
A meta-analysis of 52 studies found no link between testosterone levels and risk-taking. In general, only studies where participants completed specific lottery-based economic tasks showed a modest association between testosterone levels and risk-taking, while other types of behavioral studies did not. Furthermore, the lack of association did not depend on participants’ sex. The paper was published in Neuroscience and Biobehavioral Reviews.
Testosterone is a hormone that belongs to a group of hormones called androgens. It is present in both males and females, but it is usually found in much higher levels in males. In males, testosterone is produced mainly in the testes; in females, smaller amounts are produced in the ovaries and adrenal glands.
Testosterone plays an important role in the development of male reproductive organs before birth and during puberty. During puberty, it contributes to changes such as a deeper voice, facial and body hair growth, increased muscle mass, and the growth of the penis and testes. In adults, testosterone helps regulate sexual desire, sperm production, bone density, red blood cell production, and muscle strength. Testosterone levels naturally vary by age, time of day, health status, sleep, stress, body fat, and the use of certain medications.
Study author Irene Sánchez Rodríguez and her colleagues note that, on average, men tend to be more prone to taking risks than women. Various hypotheses have been proposed to explain this gender gap. One prominent biological theory states that the gap is produced by differences in testosterone levels. Another theory, the “dual-hormone hypothesis,” suggests that the behavioral effects of testosterone actually depend on concurrent levels of cortisol, the body’s main stress hormone.
However, studies have not clearly supported the link between testosterone and risk-taking. While some studies have reported that individuals with higher testosterone levels were somewhat more prone to taking financial or physical risks, other studies have found absolutely no association.
The authors of this study conducted a meta-analysis aimed at synthesizing the existing findings to clarify the association between testosterone levels and risk-taking. They searched scientific databases—Google Scholar, PubMed, and Scopus—using “risk seeking,” “risk attitude,” and “risk aversion” as search terms. They looked for studies conducted on humans and sought to include studies examining testosterone alone as well as those testing the dual-hormone hypothesis.
To be included, studies needed to report a statistical association between testosterone and risk preference, to either measure or administer testosterone, and to use at least one behavioral or self-report measure of risk preference. Studies also needed to be written in English, Spanish, or Italian, and provide sufficient data to allow the researchers to calculate an “effect size” (the strength of the link between testosterone levels and risk-taking). In the end, 52 studies comprising 17,340 participants were included in the analyses.
These studies measured risk in various ways, such as gambling games, balloon-popping tasks, or self-reported questionnaires. They also measured testosterone in different ways: some studies used direct blood or saliva tests, some administered experimental doses of the hormone, and some relied on “morphological proxies” (like the ratio of a person’s index and ring fingers, which is theoretically linked to testosterone exposure in the womb).
When the researchers aggregated the data, the results showed that the overall association between testosterone levels and risk-taking across all 52 studies was practically zero. In other words, having high or low testosterone did not reliably predict whether a person would take a risk.
While the overall effect was zero, the data reported by individual studies were very heterogeneous—some studies reported a positive association (higher testosterone – higher risk-taking), while others reported a negative association (higher testosterone – lower risk-taking).
Further analyses revealed why the results varied so wildly. The researchers found that the method of measurement heavily influenced the outcome. For example, only studies that used lottery-based economic tasks to measure risk-taking showed a modest positive association, while studies measuring risk-taking via other methods (like impulsive games or self-reporting) did not. Similarly, the researchers noted that studies relying on indirect finger measurements sometimes hinted at a link, while highly rigorous studies using direct hormone measurements or administration did not.
Importantly, the lack of an association between testosterone levels and risk-taking did not depend on sex, meaning the relationship (or lack thereof) was no different in males than in females.
“Overall, the evidence challenges the notion that testosterone provides a general hormonal basis for human risk preferences,” the study authors concluded. “Instead, findings support a biopsychosocial framework in which ‘risk taking’ reflects the interaction of task demands, cognitive–affective processes, and situational context, with endocrine effects appearing narrow, context-dependent, and method-specific.”
The study contributes to the scientific knowledge surrounding the behavioral effects of testosterone, suggesting that societal and psychological factors likely play a much larger role in risk-taking than single hormones. However, the study authors note that their search did not yield a sufficient number of appropriate studies to reliably examine the dual-hormone hypothesis (whether a specific interaction between cortisol and testosterone might predict risk-taking).
The paper, “No relationship between testosterone and risk aversion: A meta-analytic review,” was authored by Irene Sánchez Rodríguez, Luca Bailo, Folco Panizza, Emiliano Ricciardi, and Francesco Bossi.
-------------------------------------------------
DAILY EMAIL DIGEST: Email [email protected] -- no subject or message needed.
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot
NYU Information for Practice puts out 400-500 good quality health-related research posts per week but its too much for many people, so that bot is limited to just subscribers. You can read it or subscribe at @PsychResearchBot
Since 1991 The National Psychologist has focused on keeping practicing psychologists current with news, information and items of interest. Check them out for more free articles, resources, and subscription information: https://www.nationalpsychologist.com
EMAIL DAILY DIGEST OF RSS FEEDS -- SUBSCRIBE: http://subscribe-article-digests.clinicians-exchange.org
READ ONLINE: http://read-the-rss-mega-archive.clinicians-exchange.org
It's primitive... but it works... mostly...
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #no relationship between testosterone and risk taking #testosterone myth debunked #risk taking meta-analysis #biopsychosocial factors #endocrine effects context dependent #lottery tasks risk study #gender differences risk taking not hormone driven #dual hormone hypothesis inconclusive #testosterone measurement methods matter #neuroscience and biobehavioral reviews study
-
DATE: May 11, 2026 at 12:00PM
SOURCE: PSYPOST.ORG** Research quality varies widely from fantastic to small exploratory studies. Please check research methods when conclusions are very important to you. **
-------------------------------------------------TITLE: The testosterone myth? Large analysis finds no link between the “macho” hormone and risk-taking
A meta-analysis of 52 studies found no link between testosterone levels and risk-taking. In general, only studies where participants completed specific lottery-based economic tasks showed a modest association between testosterone levels and risk-taking, while other types of behavioral studies did not. Furthermore, the lack of association did not depend on participants’ sex. The paper was published in Neuroscience and Biobehavioral Reviews.
Testosterone is a hormone that belongs to a group of hormones called androgens. It is present in both males and females, but it is usually found in much higher levels in males. In males, testosterone is produced mainly in the testes; in females, smaller amounts are produced in the ovaries and adrenal glands.
Testosterone plays an important role in the development of male reproductive organs before birth and during puberty. During puberty, it contributes to changes such as a deeper voice, facial and body hair growth, increased muscle mass, and the growth of the penis and testes. In adults, testosterone helps regulate sexual desire, sperm production, bone density, red blood cell production, and muscle strength. Testosterone levels naturally vary by age, time of day, health status, sleep, stress, body fat, and the use of certain medications.
Study author Irene Sánchez Rodríguez and her colleagues note that, on average, men tend to be more prone to taking risks than women. Various hypotheses have been proposed to explain this gender gap. One prominent biological theory states that the gap is produced by differences in testosterone levels. Another theory, the “dual-hormone hypothesis,” suggests that the behavioral effects of testosterone actually depend on concurrent levels of cortisol, the body’s main stress hormone.
However, studies have not clearly supported the link between testosterone and risk-taking. While some studies have reported that individuals with higher testosterone levels were somewhat more prone to taking financial or physical risks, other studies have found absolutely no association.
The authors of this study conducted a meta-analysis aimed at synthesizing the existing findings to clarify the association between testosterone levels and risk-taking. They searched scientific databases—Google Scholar, PubMed, and Scopus—using “risk seeking,” “risk attitude,” and “risk aversion” as search terms. They looked for studies conducted on humans and sought to include studies examining testosterone alone as well as those testing the dual-hormone hypothesis.
To be included, studies needed to report a statistical association between testosterone and risk preference, to either measure or administer testosterone, and to use at least one behavioral or self-report measure of risk preference. Studies also needed to be written in English, Spanish, or Italian, and provide sufficient data to allow the researchers to calculate an “effect size” (the strength of the link between testosterone levels and risk-taking). In the end, 52 studies comprising 17,340 participants were included in the analyses.
These studies measured risk in various ways, such as gambling games, balloon-popping tasks, or self-reported questionnaires. They also measured testosterone in different ways: some studies used direct blood or saliva tests, some administered experimental doses of the hormone, and some relied on “morphological proxies” (like the ratio of a person’s index and ring fingers, which is theoretically linked to testosterone exposure in the womb).
When the researchers aggregated the data, the results showed that the overall association between testosterone levels and risk-taking across all 52 studies was practically zero. In other words, having high or low testosterone did not reliably predict whether a person would take a risk.
While the overall effect was zero, the data reported by individual studies were very heterogeneous—some studies reported a positive association (higher testosterone – higher risk-taking), while others reported a negative association (higher testosterone – lower risk-taking).
Further analyses revealed why the results varied so wildly. The researchers found that the method of measurement heavily influenced the outcome. For example, only studies that used lottery-based economic tasks to measure risk-taking showed a modest positive association, while studies measuring risk-taking via other methods (like impulsive games or self-reporting) did not. Similarly, the researchers noted that studies relying on indirect finger measurements sometimes hinted at a link, while highly rigorous studies using direct hormone measurements or administration did not.
Importantly, the lack of an association between testosterone levels and risk-taking did not depend on sex, meaning the relationship (or lack thereof) was no different in males than in females.
“Overall, the evidence challenges the notion that testosterone provides a general hormonal basis for human risk preferences,” the study authors concluded. “Instead, findings support a biopsychosocial framework in which ‘risk taking’ reflects the interaction of task demands, cognitive–affective processes, and situational context, with endocrine effects appearing narrow, context-dependent, and method-specific.”
The study contributes to the scientific knowledge surrounding the behavioral effects of testosterone, suggesting that societal and psychological factors likely play a much larger role in risk-taking than single hormones. However, the study authors note that their search did not yield a sufficient number of appropriate studies to reliably examine the dual-hormone hypothesis (whether a specific interaction between cortisol and testosterone might predict risk-taking).
The paper, “No relationship between testosterone and risk aversion: A meta-analytic review,” was authored by Irene Sánchez Rodríguez, Luca Bailo, Folco Panizza, Emiliano Ricciardi, and Francesco Bossi.
-------------------------------------------------
DAILY EMAIL DIGEST: Email [email protected] -- no subject or message needed.
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot
NYU Information for Practice puts out 400-500 good quality health-related research posts per week but its too much for many people, so that bot is limited to just subscribers. You can read it or subscribe at @PsychResearchBot
Since 1991 The National Psychologist has focused on keeping practicing psychologists current with news, information and items of interest. Check them out for more free articles, resources, and subscription information: https://www.nationalpsychologist.com
EMAIL DAILY DIGEST OF RSS FEEDS -- SUBSCRIBE: http://subscribe-article-digests.clinicians-exchange.org
READ ONLINE: http://read-the-rss-mega-archive.clinicians-exchange.org
It's primitive... but it works... mostly...
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #no relationship between testosterone and risk taking #testosterone myth debunked #risk taking meta-analysis #biopsychosocial factors #endocrine effects context dependent #lottery tasks risk study #gender differences risk taking not hormone driven #dual hormone hypothesis inconclusive #testosterone measurement methods matter #neuroscience and biobehavioral reviews study
-
DATE: May 11, 2026 at 12:00PM
SOURCE: PSYPOST.ORG** Research quality varies widely from fantastic to small exploratory studies. Please check research methods when conclusions are very important to you. **
-------------------------------------------------TITLE: The testosterone myth? Large analysis finds no link between the “macho” hormone and risk-taking
A meta-analysis of 52 studies found no link between testosterone levels and risk-taking. In general, only studies where participants completed specific lottery-based economic tasks showed a modest association between testosterone levels and risk-taking, while other types of behavioral studies did not. Furthermore, the lack of association did not depend on participants’ sex. The paper was published in Neuroscience and Biobehavioral Reviews.
Testosterone is a hormone that belongs to a group of hormones called androgens. It is present in both males and females, but it is usually found in much higher levels in males. In males, testosterone is produced mainly in the testes; in females, smaller amounts are produced in the ovaries and adrenal glands.
Testosterone plays an important role in the development of male reproductive organs before birth and during puberty. During puberty, it contributes to changes such as a deeper voice, facial and body hair growth, increased muscle mass, and the growth of the penis and testes. In adults, testosterone helps regulate sexual desire, sperm production, bone density, red blood cell production, and muscle strength. Testosterone levels naturally vary by age, time of day, health status, sleep, stress, body fat, and the use of certain medications.
Study author Irene Sánchez Rodríguez and her colleagues note that, on average, men tend to be more prone to taking risks than women. Various hypotheses have been proposed to explain this gender gap. One prominent biological theory states that the gap is produced by differences in testosterone levels. Another theory, the “dual-hormone hypothesis,” suggests that the behavioral effects of testosterone actually depend on concurrent levels of cortisol, the body’s main stress hormone.
However, studies have not clearly supported the link between testosterone and risk-taking. While some studies have reported that individuals with higher testosterone levels were somewhat more prone to taking financial or physical risks, other studies have found absolutely no association.
The authors of this study conducted a meta-analysis aimed at synthesizing the existing findings to clarify the association between testosterone levels and risk-taking. They searched scientific databases—Google Scholar, PubMed, and Scopus—using “risk seeking,” “risk attitude,” and “risk aversion” as search terms. They looked for studies conducted on humans and sought to include studies examining testosterone alone as well as those testing the dual-hormone hypothesis.
To be included, studies needed to report a statistical association between testosterone and risk preference, to either measure or administer testosterone, and to use at least one behavioral or self-report measure of risk preference. Studies also needed to be written in English, Spanish, or Italian, and provide sufficient data to allow the researchers to calculate an “effect size” (the strength of the link between testosterone levels and risk-taking). In the end, 52 studies comprising 17,340 participants were included in the analyses.
These studies measured risk in various ways, such as gambling games, balloon-popping tasks, or self-reported questionnaires. They also measured testosterone in different ways: some studies used direct blood or saliva tests, some administered experimental doses of the hormone, and some relied on “morphological proxies” (like the ratio of a person’s index and ring fingers, which is theoretically linked to testosterone exposure in the womb).
When the researchers aggregated the data, the results showed that the overall association between testosterone levels and risk-taking across all 52 studies was practically zero. In other words, having high or low testosterone did not reliably predict whether a person would take a risk.
While the overall effect was zero, the data reported by individual studies were very heterogeneous—some studies reported a positive association (higher testosterone – higher risk-taking), while others reported a negative association (higher testosterone – lower risk-taking).
Further analyses revealed why the results varied so wildly. The researchers found that the method of measurement heavily influenced the outcome. For example, only studies that used lottery-based economic tasks to measure risk-taking showed a modest positive association, while studies measuring risk-taking via other methods (like impulsive games or self-reporting) did not. Similarly, the researchers noted that studies relying on indirect finger measurements sometimes hinted at a link, while highly rigorous studies using direct hormone measurements or administration did not.
Importantly, the lack of an association between testosterone levels and risk-taking did not depend on sex, meaning the relationship (or lack thereof) was no different in males than in females.
“Overall, the evidence challenges the notion that testosterone provides a general hormonal basis for human risk preferences,” the study authors concluded. “Instead, findings support a biopsychosocial framework in which ‘risk taking’ reflects the interaction of task demands, cognitive–affective processes, and situational context, with endocrine effects appearing narrow, context-dependent, and method-specific.”
The study contributes to the scientific knowledge surrounding the behavioral effects of testosterone, suggesting that societal and psychological factors likely play a much larger role in risk-taking than single hormones. However, the study authors note that their search did not yield a sufficient number of appropriate studies to reliably examine the dual-hormone hypothesis (whether a specific interaction between cortisol and testosterone might predict risk-taking).
The paper, “No relationship between testosterone and risk aversion: A meta-analytic review,” was authored by Irene Sánchez Rodríguez, Luca Bailo, Folco Panizza, Emiliano Ricciardi, and Francesco Bossi.
-------------------------------------------------
DAILY EMAIL DIGEST: Email [email protected] -- no subject or message needed.
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot
NYU Information for Practice puts out 400-500 good quality health-related research posts per week but its too much for many people, so that bot is limited to just subscribers. You can read it or subscribe at @PsychResearchBot
Since 1991 The National Psychologist has focused on keeping practicing psychologists current with news, information and items of interest. Check them out for more free articles, resources, and subscription information: https://www.nationalpsychologist.com
EMAIL DAILY DIGEST OF RSS FEEDS -- SUBSCRIBE: http://subscribe-article-digests.clinicians-exchange.org
READ ONLINE: http://read-the-rss-mega-archive.clinicians-exchange.org
It's primitive... but it works... mostly...
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #no relationship between testosterone and risk taking #testosterone myth debunked #risk taking meta-analysis #biopsychosocial factors #endocrine effects context dependent #lottery tasks risk study #gender differences risk taking not hormone driven #dual hormone hypothesis inconclusive #testosterone measurement methods matter #neuroscience and biobehavioral reviews study
-
A cis-man injecting testosterone is "gender affirming care" and should be called that.
Real Men don't for health scams from grifters, they have more self respect -
Il y a 8 ans : Gonzalo Najar, vainqueur du Tour de San Juan, positif à l'EPO-CERA https://www.cyclisme-dopage.com/actualite/2018-05-06-cyclisme-dopage.htm #cyclisme #dopage #EPO #CERA #TourDeSanJuan #GonzaloNajar #testostérone
-
Il y a 8 ans : Gonzalo Najar, vainqueur du Tour de San Juan, positif à l'EPO-CERA https://www.cyclisme-dopage.com/actualite/2018-05-06-cyclisme-dopage.htm #cyclisme #dopage #EPO #CERA #TourDeSanJuan #GonzaloNajar #testostérone
-
Il y a 18 ans : L'Espagnol Patxi Vila contrôlé positif à la testostérone https://www.cyclisme-dopage.com/actualite/2008-05-06-tsr-ch.htm #cyclisme #dopage #PatxiVila #Lampre #testostérone #Giro2008
-
Il y a 18 ans : L'Espagnol Patxi Vila contrôlé positif à la testostérone https://www.cyclisme-dopage.com/actualite/2008-05-06-tsr-ch.htm #cyclisme #dopage #PatxiVila #Lampre #testostérone #Giro2008
-
Il y a 12 ans : Ricco pris une nouvelle fois les mains dans le sac https://www.cyclisme-dopage.com/actualite/2014-04-30-rtbf-be.htm #cyclisme #dopage #testostérone #EPO #CERA #TDF2008 #RiccardoRicco
-
J'ai mis à jour mon article et revue de littérature sur la chirurgie de masculinisation vocale.
J'ai rajouté un article paru récemment, une série de 2 cas d'injections de testostérone dans les cordes vocales.
Il s'agit des 1ères données portant chez des personnes n'ayant jamais pris de testostérone (une série précédente de 8 cas existe mais les résultats n'ont pas été publiés)
Et j'en ai profité pour rajouter un tableau récapitulatif des (rares) données qu'on a sur cette intervention.J'ai un rdv chez une chir qui fait des VFS (glotto/crico) et qui a minima connaît les VMS aussi mi-mai, je ferais sûrement un retour si elle dit la pratiquer vu que pour le moment on n'a aucune adresse connue en France 🤞
-
J'ai mis à jour mon article et revue de littérature sur la chirurgie de masculinisation vocale.
J'ai rajouté un article paru récemment, une série de 2 cas d'injections de testostérone dans les cordes vocales.
Il s'agit des 1ères données portant chez des personnes n'ayant jamais pris de testostérone (une série précédente de 8 cas existe mais les résultats n'ont pas été publiés)
Et j'en ai profité pour rajouter un tableau récapitulatif des (rares) données qu'on a sur cette intervention.J'ai un rdv chez une chir qui fait des VFS (glotto/crico) et qui a minima connaît les VMS aussi mi-mai, je ferais sûrement un retour si elle dit la pratiquer vu que pour le moment on n'a aucune adresse connue en France 🤞
-
J'ai mis à jour mon article et revue de littérature sur la chirurgie de masculinisation vocale.
J'ai rajouté un article paru récemment, une série de 2 cas d'injections de testostérone dans les cordes vocales.
Il s'agit des 1ères données portant chez des personnes n'ayant jamais pris de testostérone (une série précédente de 8 cas existe mais les résultats n'ont pas été publiés)
Et j'en ai profité pour rajouter un tableau récapitulatif des (rares) données qu'on a sur cette intervention.J'ai un rdv chez une chir qui fait des VFS (glotto/crico) et qui a minima connaît les VMS aussi mi-mai, je ferais sûrement un retour si elle dit la pratiquer vu que pour le moment on n'a aucune adresse connue en France 🤞
-
J'ai mis à jour mon article et revue de littérature sur la chirurgie de masculinisation vocale.
J'ai rajouté un article paru récemment, une série de 2 cas d'injections de testostérone dans les cordes vocales.
Il s'agit des 1ères données portant chez des personnes n'ayant jamais pris de testostérone (une série précédente de 8 cas existe mais les résultats n'ont pas été publiés)
Et j'en ai profité pour rajouter un tableau récapitulatif des (rares) données qu'on a sur cette intervention.J'ai un rdv chez une chir qui fait des VFS (glotto/crico) et qui a minima connaît les VMS aussi mi-mai, je ferais sûrement un retour si elle dit la pratiquer vu que pour le moment on n'a aucune adresse connue en France 🤞
-
J'ai mis à jour mon article et revue de littérature sur la chirurgie de masculinisation vocale.
J'ai rajouté un tableau récapitulatif des (rares) données qu'on a sur les injections de testostérone dans les cordes vocales à l'occasion de la parution d'une série de 2 cas de cette intervention.
Il s'agit des 1ères données portant chez des personnes n'ayant jamais pris de testostérone (une série précédente de 8 cas existe mais les résultats n'ont pas été publiés).
L'étude montre une baisse de la fréquence fondamentale avec cette technique (20Hz chez l'une et 40Hz chez l'autre). Pour comparer, une thyroplastie type III c'est ~50Hz (très approximativement on manque de données, et pour les injections les échantillons sont vraiment très très faibles : 5 cas trans publiés uniquement).J'ai un rdv chez une chir qui fait des VFS (glotto/crico) et qui a minima connaît les VMS aussi mi-mai, je ferais sûrement un retour si elle dit la pratiquer vu que pour le moment on n'a aucune adresse connue en France 🤞
-
Ah, the wonders of science: apparently, a shot of #testosterone can turn a spineless Democrat into a right-wing warrior 💪🦸♂️, but alas, the only real transformation here is the website, which has successfully evolved into a 403 error page 🙈🔒. Who knew #political insights were so exclusive? 😂
https://www.psypost.org/scientists-discover-weak-dems-have-highest-testosterone-but-theres-an-intriguing-twist/ #science #humor #satire #403error #HackerNews #ngated -
Ah, the wonders of science: apparently, a shot of #testosterone can turn a spineless Democrat into a right-wing warrior 💪🦸♂️, but alas, the only real transformation here is the website, which has successfully evolved into a 403 error page 🙈🔒. Who knew #political insights were so exclusive? 😂
https://www.psypost.org/scientists-discover-weak-dems-have-highest-testosterone-but-theres-an-intriguing-twist/ #science #humor #satire #403error #HackerNews #ngated -
Ah, the wonders of science: apparently, a shot of #testosterone can turn a spineless Democrat into a right-wing warrior 💪🦸♂️, but alas, the only real transformation here is the website, which has successfully evolved into a 403 error page 🙈🔒. Who knew #political insights were so exclusive? 😂
https://www.psypost.org/scientists-discover-weak-dems-have-highest-testosterone-but-theres-an-intriguing-twist/ #science #humor #satire #403error #HackerNews #ngated -
Ah, the wonders of science: apparently, a shot of #testosterone can turn a spineless Democrat into a right-wing warrior 💪🦸♂️, but alas, the only real transformation here is the website, which has successfully evolved into a 403 error page 🙈🔒. Who knew #political insights were so exclusive? 😂
https://www.psypost.org/scientists-discover-weak-dems-have-highest-testosterone-but-theres-an-intriguing-twist/ #science #humor #satire #403error #HackerNews #ngated -
Ah, the wonders of science: apparently, a shot of #testosterone can turn a spineless Democrat into a right-wing warrior 💪🦸♂️, but alas, the only real transformation here is the website, which has successfully evolved into a 403 error page 🙈🔒. Who knew #political insights were so exclusive? 😂
https://www.psypost.org/scientists-discover-weak-dems-have-highest-testosterone-but-theres-an-intriguing-twist/ #science #humor #satire #403error #HackerNews #ngated -
@theleftistlawyer @shansterable
I support #standardization of #medical #licensing for #providers and #facilities (#doctors' #offices, #hospitals, #longtermCare, etc.).
I oppose government intrusion into the provider #patient #relationship.
If a #woman is using #estrogen patches, it's none of your business why.
Same for a #man using #testosterone. If he's trying to #cheat at #sports, the #league can manage it.
-
@theleftistlawyer @shansterable
I support #standardization of #medical #licensing for #providers and #facilities (#doctors' #offices, #hospitals, #longtermCare, etc.).
I oppose government intrusion into the provider #patient #relationship.
If a #woman is using #estrogen patches, it's none of your business why.
Same for a #man using #testosterone. If he's trying to #cheat at #sports, the #league can manage it.
-
@theleftistlawyer @shansterable
I support #standardization of #medical #licensing for #providers and #facilities (#doctors' #offices, #hospitals, #longtermCare, etc.).
I oppose government intrusion into the provider #patient #relationship.
If a #woman is using #estrogen patches, it's none of your business why.
Same for a #man using #testosterone. If he's trying to #cheat at #sports, the #league can manage it.
-
@theleftistlawyer @shansterable
I support #standardization of #medical #licensing for #providers and #facilities (#doctors' #offices, #hospitals, #longtermCare, etc.).
I oppose government intrusion into the provider #patient #relationship.
If a #woman is using #estrogen patches, it's none of your business why.
Same for a #man using #testosterone. If he's trying to #cheat at #sports, the #league can manage it.
-
@theleftistlawyer @shansterable
I support #standardization of #medical #licensing for #providers and #facilities (#doctors' #offices, #hospitals, #longtermCare, etc.).
I oppose government intrusion into the provider #patient #relationship.
If a #woman is using #estrogen patches, it's none of your business why.
Same for a #man using #testosterone. If he's trying to #cheat at #sports, the #league can manage it.
-
Il y a 17 ans : Greenpeace: révélations sur l'affaire d'espionnage https://www.cyclisme-dopage.com/actualite/2009-04-15-lexpress.htm #cyclisme #dopage #AFLD #FloydLandis #testostérone #Greenpeace #EDF #DGSE
-
Il y a 17 ans : Greenpeace: révélations sur l'affaire d'espionnage https://www.cyclisme-dopage.com/actualite/2009-04-15-lexpress.htm #cyclisme #dopage #AFLD #FloydLandis #testostérone #Greenpeace #EDF #DGSE
-
Il y a 17 ans : Greenpeace: révélations sur l'affaire d'espionnage https://www.cyclisme-dopage.com/actualite/2009-04-15-lexpress.htm #cyclisme #dopage #AFLD #FloydLandis #testostérone #Greenpeace #EDF #DGSE
-
Il y a 21 ans : « La nouvelle loi antidopage blanchit 80% des cyclistes positifs l'an passé ! » https://www.cyclisme-dopage.com/dossierdefond/2005-04-14-cyclismag.htm #cyclisme #dopage #corticoïdes #testostérone #PhilippeGaumont #Kenacort #EPO #HormonesDeCroissance #Caféine #AUT
-
Toujours sur le sujet de la fertilité transmasc, une étude rétrospective sur les résultats de stimulations ovariennes (pour FIV ou pour préservation d'ovocytes) chez des personnes trans ayant pris de la testostérone ou non[1]. Elle comprends 46 cycles chez 36 personnes différentes, dont 20 cyles (14 personnes) ayant été sous T auparavant. Ce qui est un échantillon très faible mais pas mal du tout pour le champs de la fertilité transmasc.
Son intérêt est qu'il y a actuellement peu de données sur les résultats en terme d'embryons/de blastocystes (structures du début du développement embryonnaire) et de naissances après la prise de T ; la majorité des données qu'on a sont sur des ovocytes préservés, pas sur leur utilisation.L'étude trouve que, en contrôlant pour l'âge, l'utilisation préalable de T est associée à moins de blastocystes de haute qualité et à moins de blastocystes en général, mais pas à une quantité d'ovocytes matures différente. Elle trouve aussi qu'un arrêt de la T pour moins de 6 mois avant la stimulation est associé à moins de blastocystes de haute qualité (mais pas à moins d'ovocytes matures récoltés) ; mais pour diverses raisons il ne faut pas penser que cette relation est causale. Elle ne trouve pas de différence significative dans le taux du nombre de naissances.
D'ailleurs la partie sur les ovocytes matures est cohérente avec une autre étude rétrospective qui ne trouvait pas d'association entre la durée d'arrêt de testostérone et le nombre d'ovocytes matures préservés[2].
En gros, la prise de T semble ne pas poser de problèmes pour la conservation d'ovocytes, mais pourrait baisser un peu l'efficacité de leur utilisation ─ ça n'implique pas qu'une grossesse et une naissance n'est pas possible, mais plutôt qu'il est possible qu'il faille plus de cycle ou un arrêt de la T plus long pour y parvenir. Tout ça à prendre avec des énormes pincettes vu les limites méthodologiques (mais c'est super de voir de plus en plus de données sur le sujet, et comment les recommandations peuvent évoluer en conséquence)
[1] : In vitro fertilization outcomes in transgender individuals with prior testosterone therapy. Rubin ES et al., 2026. https://doi.org/10.1093/humrep/deag003
[2] : Timing of testosterone discontinuation and assisted reproductive technology outcomes in transgender patients: a cohort study. Albar M et al., 2023. https://doi.org/10.1016/j.xfre.2023.01.004
-
Je vais encore parler du dépistage du cancer du col de l'utérus (désolé) mais cette fois pour un truc nouveau : une étude qui compare l'usage d'un examen cytologique/frottis à l'usage d'un test HPV-HR[1].
Quand on fait un prélevement cervico-vaginal (frottis) on peut soit regarder l'apparence des cellules au microscope en laboratoire (cytologie) ou tester la présence de variants hauts risque du virus HPV dans ces cellules (test HPV-HR).
Ce que l'étude montre, c'est que chez les personnes transmasculines sous testostérone, la cytologie n'est pas plus efficace que le test HPV-HR pour réduire les faux positifs (sensibilité et sensitivité des deux pour prédire la présence d'une lésion inquiétante, CIN2+, similaires). Les deux types de tests ont une chance similaire d'indiquer une lésion (dysplasie) en cas de résultat positif (PPV, positive predictive value).Les auteurices conseillent donc de favoriser l'utilisation des tests HPV en 1ère intention chez les personnes transmasc sous T, notamment psk les examens cytologiques sur les frottis sont plus souvent non concluants chez les personnes sous T[1,2], et passer aux tests HPV pourrait permettre d'éviter des examens pelviens supplémentaires inutiles. Bonus non-négligeable, les test HPV peuvent être des auto-prélevements vaginaux, qu'on se fait soi-même, qui tendent à être bien plus appréciées des personnes transmasculines[3].
Pour info en France, les reco HAS[4] sont d'utiliser des tests cytologiques chez les personnes (bon la HAS dit femmes...) jeunes, à 25 et 26 ans, puis à 29 ans si normal, et de passer au test HPV seulement après (à 32 ans, puis tous les 5 ans si tests négatifs), en raison d'un risque de surdiagnostic si on utilise les tests HPV chez les plus jeunes. La HAS recommande de proposer l'auto-prélevement aux personnes qui peu/pas dépistées.
[1] : Cytology and High-Risk Human Papillomavirus Testing Performance for Cervical Cancer Screening in Transmasculine Patients. Bolten K et al., 2026. https://doi.org/10.1177/15409996261433761
[2] : Cervicovaginal and Anal Self-Sampling for Human Papillomavirus Testing in a Transgender and Gender Diverse Population Assigned Female at Birth: Comfort, Difficulty, and Willingness to Use. Welsh EF et al., 2024. https://doi.org/10.1089/lgbt.2023.0336
[3] : Cytology and LGBT+ health: establishing inclusive cancer screening programs. Compton ML et al., 2022. https://doi.org/10.1016/j.jasc.2022.06.003
[4] : Évaluation de la recherche des papillomavirus humains (HPV) en dépistage primaire des lésions précancéreuses et cancéreuses du col de l’utérus, HAS, 2019. https://www.has-sante.fr/jcms/c_2806160/fr/evaluation-de-la-recherche-des-papillomavirus-humains-hpv-en-depistage-primaire-des-lesions-precancereuses-et-cancereuses-du-col-de-l-uterus-et-de-la-place-du-double-immuno-marquage-p16/ki67
-
♂️ “Modern scientists generally agree that early humans ate majority plant-based diets, and the meat they did eat was often collected by scavenging rather than hunting. …but the reality hasn’t stopped modern humans from trying to replicate our “fantasy image,” as Rosenfeld puts it, of humans (and human men especially) as big consumers of meat.” #menshealth #sexuality #masculinity #testosterone #Men @menshealth https://www.huffingtonpost.co.uk/entry/manosphere-eating-meat_uk_69c692b4e4b0a6ee60c46649?utm_source=flipboard&utm_content=topic%2Fmen%27shealth
-
Il y a 17 ans : Bernhard Kohl raconte ses années dopage https://www.cyclisme-dopage.com/actualite/2009-03-31-20minutes.htm #cyclisme #dopage #BernhardKohl #EPO #HormonesDeCroissance #TDF2008 #Testostérone #Insuline #StefanMatschiner #Humanplasma
-
Il y a 14 ans : Damiano Cunego et Alessandro Ballan devant la justice concernant « L'Affaire Lampre » https://www.cyclisme-dopage.com/actualite/2012-03-29-sudinfo-be.htm #cyclisme #dopage #Ballan #Cunego #Lampre #GiuseppeSaronni #EPO #anabolisants #testostérone #HormonesDeCroissance
-
Il y a 5 ans : Richard Freeman, ancien membre de la Sky, radié de l'ordre des médecins https://www.cyclisme-dopage.com/actualite/2021-03-19-rtbf-be.htm #cyclisme #dopage #RichardFreeman #TeamSky #Testostérone
-
Il y a 22 ans : Gaumont détaille les méthodes pour tricher https://www.cyclisme-dopage.com/actualite/2004-03-15-yahoo-afp.htm #cyclisme #dopage #Cofidis #HormonesDeCroissance #PhilippeGaumont #Testostérone #Autotransfusion #Nandrolone
-
Il y a 18 ans : Sinkewitz se défend d'avoir dénoncé Klöden https://www.cyclisme-dopage.com/actualite/2008-03-12-cyberpresse-ca.htm #cyclisme #dopage #AndreasKloden #MatthiasKessler #PatrikSinkewitz #TMobile #Testostérone #Astana
-
Il y a 5 ans : L'ex-médecin de Sky reconnu coupable d'avoir commandé de la testostérone à des fins de dopage https://www.cyclisme-dopage.com/actualite/2021-03-12-lemonde-fr.htm #cyclisme #dopage #ChrisFroome #RichardFreeman #TeamSky #Testogel #Testostérone #TDF2012
-
Il y a 12 ans : « Lance Armstrong se dopait déjà en 1992 » https://www.cyclisme-dopage.com/actualite/2014-03-04-sudinfo-be.htm #cyclisme #dopage #JulietMacur #LanceArmstrong #JO1992 #EPO #HormonesDeCroissance #amphétamines #cortisone #testostérone
-
Il y a 8 ans : La Sky, l'équipe de Froome, aurait commandé de la testostérone https://www.cyclisme-dopage.com/actualite/2018-03-02-leprogres-fr.htm #cyclisme #dopage #Salbutamol #TeamSky #Testostérone #Vuelta2017 #RichardFreeman
-
Il y a 11 ans : Où l'on reparle de la collaboration de Jalabert avec le docteur Ferrari https://www.cyclisme-dopage.com/actualite/2015-02-27-lemonde-fr2.htm #cyclisme #dopage #PierreBallester #FrancescoConconi #MicheleFerrari #LaurentJalabert #ONCE #EPO #testostérone #JacquesMombet
-
Il y a 18 ans : Deux ans de suspension confirmés pour l'Italien Fertonani https://www.cyclisme-dopage.com/breves/breves-2008-02-25-tsr-ch.htm #cyclisme #dopage #MarcoFertonani #CONI #testostérone #Tourméditerranéen #CaisseDEpargne
-
Il y a 16 ans : Landis n'aurait rien reçu https://www.cyclisme-dopage.com/actualite/2010-02-17-lequipe.htm #cyclisme #dopage #AFLD #FloydLandis #TDF2006 #testostérone
-
Il y a 16 ans : Landis n'aurait rien reçu https://www.cyclisme-dopage.com/actualite/2010-02-17-lequipe.htm #cyclisme #dopage #AFLD #FloydLandis #TDF2006 #testostérone
-
Il y a 16 ans : Landis n'aurait rien reçu https://www.cyclisme-dopage.com/actualite/2010-02-17-lequipe.htm #cyclisme #dopage #AFLD #FloydLandis #TDF2006 #testostérone
-
Il y a 22 ans : Fassa Bortolo, dans la roue d'une équipe habituée des podiums, repaire de coureurs au passé trouble https://www.cyclisme-dopage.com/breves/breves-2004-02-14-letemps-ch.htm #cyclisme #dopage #GiancarloFerretti #DenisZanette #EPO #hormonesdecroissance #testostérone #AlbertoVolpi #VladimirGustov #FabioSacchi
-
Il y a 8 ans : Les stéroïdes anabolisants, un poison pour le cerveau https://www.cyclisme-dopage.com/dossierdefond/2018-02-13-lemonde-fr.htm #cyclisme #dopage #stéroïdes #anabolisants #testostérone #cerveau #cocaïne #corticoïdes